Wound News and Research

RSS

American Biotech Labs' ASAP Antibacterial Silver Gel receives FDA 510(k) medical device clearance

American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), today announced that the company has obtained clearance by the U.S. Food and Drug Administration (FDA) to market its ASAP Antibacterial Silver Wound Dressing Gel as a prescription 510(k) medical device throughout the United States. Clifton Mining Company is a major shareholder in American Biotech Labs.

17 Nov 2009

Hospitals should expand quality control guidelines to improve surgical complications in older patients

The elderly are more vulnerable to problems after a major surgical procedure than younger patients, but a team of investigators using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) suggest that one way to improve surgical results in this age group is to have hospitals expand their quality control guidelines to include more types of surgery-related complications.

17 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Misonix inks a three-year distribution agreement with Xenith in Dubai

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year distribution agreement with Xenith, LLC, based in Dubai, UAE, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider.

13 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

FDA regulatory clearance for Kensey Nash's ECM product

Kensey Nash Corporation, a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Fort Hood shootings: Oral and maxillofacial surgeons among first responders

Before news of the November 5, Fort Hood shootings reached the public, oral and maxillofacial surgeons Major Mark E. Ranschaert, DMD and Major Joseph Dylan Bowles, DDS were in Fort Hood's Carl R. Darnall Army Medical Center emergency room working to save the lives of the shooter's victims.

11 Nov 2009

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation. According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation. Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

10 Nov 2009

Single reimbursement code for NPWT devices: Smith & Nephew endorses decision

The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.

9 Nov 2009

American Academy of Nursing inducts seven editors of LWW as Academy Fellows

The American Academy of Nursing today inducted seven editors and editorial board members of Lippincott Williams & Wilkins (LWW) nursing publications as Academy Fellows. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

7 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

Smith & Nephew reports third quarter 2009 financial results

Smith & Nephew Q3 Results - continued strong profit performance 6 November 2009 Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces its results for the third quarter ended 26 September 2009.

6 Nov 2009

Heal2gether Partnership Program for diabetes patients and their physicians launched

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine and the maker of Dermagraft®, launched during American Diabetes Month the Heal2gether Partnership Program for diabetes patients and their physicians.

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Puricore reports increase in sales of 25% in Q3

PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009.

3 Nov 2009

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

3 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

New on-line job resource center launched by NAWC

The National Alliance of Wound Care (NAWC(®)), the largest, multi-disciplinary, wound care credentialing and association organization, announced today, the launch of their wound care specialty on-line Job Resource Center in conjunction with their newly redesigned website at, www.nawccb.org.

2 Nov 2009

MRSA bloodstream infection linked to high mortality rate

A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study.

2 Nov 2009